Sanofi Terminates MOBILIZE Phase 3 Study Of Riliprubart In Chronic Inflammatory Demyelinating Polyneuropathy, Flags No Safety Signals, No Financial Impact

Benzinga Newsdesk www.benzinga.com Neutral 80.8%

Neg 0% Neu 80.8% Pos 0%

Comments

No comments yet. Be the first!